Gamco Investors INC. ET AL lifted its holdings in shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) by 34.1% in the third quarter, Holdings Channel.com reports. The fund owned 220,000 shares of the company’s stock after purchasing an additional 56,000 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Meridian Bioscience were worth $2,088,000 at the end of the most recent reporting period.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Other large investors have also added to or reduced their stakes in the company. Coastal Capital Group Inc. bought a new position in shares of Meridian Bioscience during the 2nd quarter worth about $25,000. Financial Gravity Wealth Inc. bought a new position in shares of Meridian Bioscience during the 2nd quarter worth about $29,000. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of Meridian Bioscience by 113.7% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,869 shares of the company’s stock worth $58,000 after acquiring an additional 2,591 shares during the period. Capital Fund Management S.A. bought a new position in shares of Meridian Bioscience during the 2nd quarter worth about $138,000. Finally, Trexquant Investment LP bought a new position in shares of Meridian Bioscience during the 2nd quarter worth about $141,000. 88.20% of the stock is owned by institutional investors.
VIVO stock traded down $0.35 during trading on Friday, hitting $7.90. 470,900 shares of the stock traded hands, compared to its average volume of 341,224. Meridian Bioscience, Inc. has a one year low of $7.62 and a one year high of $19.84. The company has a 50 day simple moving average of $9.64 and a 200 day simple moving average of $10.75. The company has a current ratio of 6.93, a quick ratio of 4.75 and a debt-to-equity ratio of 0.40. The stock has a market cap of $431.39 million, a price-to-earnings ratio of 10.68 and a beta of 0.37.
Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.09 by $0.04. Meridian Bioscience had a net margin of 12.65% and a return on equity of 17.82%. The company had revenue of $50.80 million during the quarter, compared to analysts’ expectations of $50.57 million. During the same quarter in the previous year, the company earned $0.20 EPS. Meridian Bioscience’s revenue was down 4.3% on a year-over-year basis. As a group, analysts predict that Meridian Bioscience, Inc. will post 0.64 earnings per share for the current fiscal year.
A number of equities analysts have recently commented on the stock. BidaskClub raised shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a report on Wednesday, October 16th. Canaccord Genuity reaffirmed a “sell” rating and set a $9.00 price objective on shares of Meridian Bioscience in a report on Wednesday, July 31st. ValuEngine raised shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Zacks Investment Research downgraded shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Sunday, November 3rd. One investment analyst has rated the stock with a sell rating and five have assigned a hold rating to the company’s stock. Meridian Bioscience presently has an average rating of “Hold” and a consensus target price of $11.25.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.
Featured Article: How is net asset value different from market price?
Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience, Inc. (NASDAQ:VIVO).